Compare Vanguard Ultra Short Bond ETF (VUSB) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Ultra Short Bond ETF vs Zoetis Inc — how do they compare? Vanguard Ultra Short Bond ETF trades at $49.69, while Zoetis Inc trades at $73.7 (market cap $31.14B). The key difference: Zoetis Inc pays a 2.81% dividend while Vanguard Ultra Short Bond ETF pays none, and Vanguard Ultra Short Bond ETF is trading nearer its 52-week high, Zoetis Inc nearer its low. Which is the better fit depends on your goals.
| VUSB | ZTS | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $50.03 | $156.76 |
52-Week Low | $49.60 | $71.91 |
Market Cap | — | $31.14B |
Enterprise Value | — | $38.70B |
Dividend Yield | — | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VUSB trades at $49.68 with minimal daily movement (+0.04%). The technical picture is bearish with moving averages signaling selling pressure, though oscillators remain neutral. Recent dividend distributions show consistent payouts, with the latest being $0.18 paid on July 6, 2026. Financial ratios are unavailable in the current data snapshot.
The outlook remains cautious due to bearish technical indicators and potential interest rate sensitivity. Recent financial media suggests short-term bond ETFs like VUSB may benefit from Fed rate increases in 2026, though the current technical weakness warrants careful monitoring of support levels.
Zoetis (ZTS) trades at $73.4, down 1.95% on the day, as technical indicators signal a bearish trend amid recent price weakness. Fundamentally, the company reported Q2 2026 EPS of $1.87, beating estimates, but revenue was flat and full-year guidance was cut due to softer pet healthcare demand. Analyst sentiment remains mixed with a consensus price target of $94.90, though recent news highlights competitive pressures and a securities class action lawsuit.
The stock presents a value opportunity given its attractive P/E of 12.29 and strong profitability margins, but near-term headwinds from U.S. companion-animal market challenges and legal overhangs pose risks. Upside depends on execution against revised 2026 targets and stabilization in core markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Vanguard Ultra Short Bond ETF
VUSB is an actively managed ETF from Vanguard that invests in a diversified portfolio of high-quality, investment-grade fixed income securities with maturities typically under two years. It is designed to offer higher yield potential than traditional money market funds while maintaining limited price volatility, making it a strategic tool for managing short-term reserves with a 6-to-18-month horizon.
Read more on VUSB →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
